|
| Exhibit 21 |
|
|
|
List of Subsidiaries |
|
|
|
|
|
Entity Name | Place of Incorporation | Ownership % as of December 31, 2022 |
BB Square Capital Investors I, LP | Delaware | 100.0% |
BB Square Capital, LLC | Delaware | 100.0% |
BB Square Holdings, LLC | Delaware | 100.0% |
BB Square Investors GP I, LLC | Delaware | 100.0% |
BB Square LP Investment, LLC | Delaware | 100.0% |
BridgeBio Chemistry, Inc. | Delaware | 100.0% |
BridgeBio Gene Therapy LLC | Delaware | 100.0% |
BridgeBio Gene Therapy Research, Inc. | Delaware | 100.0% |
BridgeBio Pharma LLC | Delaware | 100.0% |
BridgeBio Services Inc. | Delaware | 100.0% |
Calcilytix Therapeutics, Inc. | Delaware | 100.0% |
Cyan Therapeutics, Inc. | Delaware | 100.0% |
DTD Therapeutics, Inc. | Delaware | 100.0% |
Eidos Therapeutics, Inc. | Delaware | 100.0% |
Sub20, Inc. | Delaware | 100.0% |
CoA Therapeutics, Inc. | Delaware | 100.0% |
Origin Biosciences, Inc. | Delaware | 99.9% |
TheRas, Inc. | Delaware | 99.9% |
Portal Therapeutics, Inc. | Delaware | 99.6% |
Adrenas Therapeutics, Inc. | Delaware | 99.1% |
QED Therapeutics, Inc. | Delaware | 99.0% |
Sub22, Inc. | Delaware | 98.5% |
Ferro Therapeutics, Inc. | Delaware | 98.2% |
Eulamin Therapeutics, Inc. | Delaware | 98.0% |
Sub21, Inc. | Delaware | 98.0% |
Aspa Therapeutics, Inc. | Delaware | 98.0% |
Cantero Therapeutics, Inc. | Delaware | 96.5% |
Venthera, Inc. | Delaware | 96.1% |
G Protein Therapeutics, Inc. | Delaware | 95.2% |
Molecular Skin Therapeutics, Inc. | Delaware | 91.4% |
Phoenix Tissue Repair, Inc. | Delaware | 85.8% |
Navire Pharma, Inc. | Delaware | 80.8% |
ML Bio Solutions, Inc. | Delaware | 76.1% |
Sen Therapeutics, Inc. | Delaware | 64.4% |
PellePharm, Inc. | Delaware | 43.2% |
Audition Therapeutics, Inc. | Delaware | 34.4% |
BridgeBio Pharma Canada, ULC | Canada | 100.0% |
BridgeBio Pharma Cayman | Cayman Islands | 100.0% |
BridgeBio France SAS | France | 100.0% |
BridgeBio Germany, GmbH | Germany | 100.0% |
BridgeBio Pharma (HK) Limited | Hong Kong | 100.0% |
BridgeBio Europe B.V. | Netherlands | 100.0% |
BridgeBio International GmbH | Switzerland | 100.0% |
BridgeBio UK Limited | United Kingdom | 100.0% |